Scientists have taken a significant step toward neutralizing Epstein-Barr virus. Scientists at Fred Hutch Cancer Center have reported an important advance in the effort to stop Epstein Barr virus (EBV ...
A new standard in wheat immune reactivity testing that adds seven new wheat markers to assess immune responses to ...
SIRPα immunotherapy include targeting overexpressed CD47 in cancers to boost macrophage activity, using dual function molecules to enhance efficacy, and innovative drug designs reducing red blood cell ...
The webinar highlights advances in high-throughput gene and protein synthesis platforms that accelerate antibody discovery and optimization. Using accurate HTP Strings DNA fragments improves cloning ...
Measles is a notifiable disease in the UK, meaning GPs and hospitals must report cases to the local Health Protection Team (HPT). If you suspect measles – even with mild symptoms – it’s important to ...
Thousands of lawsuits in the U.S. allege that the agrochemical maker Bayer failed to warn people that its popular weedkiller ...
The Fetch dvm360 Conference series is returning to Nashville, Tennessee, May 29-30, 2026. This continuing education (CE) event offers peer-to-peer networking, hands-on labs, and nearly 150 learning ...
The neuron’s inner scaffold, once viewed as static support, now looks like a gatekeeper. Research findings are available ...
Morning Overview on MSN
Scientists finally uncover what went wrong with J&J’s COVID vaccine
When reports of rare but severe blood clots emerged after Johnson & Johnson’s COVID vaccine, they threatened to overshadow an otherwise successful immunization campaign and left scientists searching ...
Sykes also cautions against the opposite mistake: overinterpreting a positive result. Subclinical exposure to Leptospira species is common, meaning a positive test—such as a visible red line or blue ...
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended ...
During the fourth quarter, Baron Opportunity Fund posted a return of 4.63% (Institutional Shares), outperforming the Russell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results